Targeting B Lymphocytes as Therapy for ANCA-Associated Vasculitis

Jason M. Golbin, Ulrich Specks

Research output: Contribution to journalReview articlepeer-review

14 Scopus citations


This article focuses on the initial results achieved with the more selective immunosuppressive approach of B-lymphocyte depletion in patients who fail cyclophosphamide or have contraindications for its use in the treatment of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). This novel approach has sparked hope for patients and physicians in their search for effective, well-tolerated therapy for AAV. B-cell depletion is now undergoing rigorous investigation in randomized clinical trials.

Original languageEnglish (US)
Pages (from-to)741-754
Number of pages14
JournalRheumatic Disease Clinics of North America
Issue number4
StatePublished - Nov 2007

ASJC Scopus subject areas

  • Rheumatology


Dive into the research topics of 'Targeting B Lymphocytes as Therapy for ANCA-Associated Vasculitis'. Together they form a unique fingerprint.

Cite this